Novel multivalent S100A8 inhibitory peptides attenuate tumor progression and metastasis by inhibiting the TLR4-dependent pathway

The tumor-elicited inflammation is closely related to tumor microenvironment during tumor progression. S100A8 , an endogenous ligand of Toll-like receptor 4 (TLR4), is known as a key molecule in the tumor microenvironment and premetastatic niche formation. We firstly generated a novel multivalent S1...

Full description

Saved in:
Bibliographic Details
Published inCancer gene therapy Vol. 30; no. 7; pp. 973 - 984
Main Authors Deguchi, Atsuko, Watanabe-Takahashi, Miho, Mishima, Taishi, Omori, Tsutomu, Ohto, Umeharu, Arashiki, Nobuto, Nakamura, Fumio, Nishikawa, Kiyotaka, Maru, Yoshiro
Format Journal Article
LanguageEnglish
Published New York Nature Publishing Group US 01.07.2023
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The tumor-elicited inflammation is closely related to tumor microenvironment during tumor progression. S100A8 , an endogenous ligand of Toll-like receptor 4 (TLR4), is known as a key molecule in the tumor microenvironment and premetastatic niche formation. We firstly generated a novel multivalent S100A8 competitive inhibitory peptide (divalent peptide3A5) against TLR4/MD-2, using the alanine scanning. Divalent peptide3A5 suppressed S100A8-mediated interleukin-8 and vascular endothelial growth factor production in human colorectal tumor SW480 cells. Using SW480-transplanted xenograft models, divalent peptide3A5 suppressed tumor progression in a dose-dependent manner. We demonstrated that combination therapy with divalent peptide3A5 and bevacizumab synergistically suppressed tumor growth in SW480 xenograft models. Using syngeneic mouse models, we found that divalent peptide3A5 improved the efficacy of anti-programmed death (PD)1 antibody, and lung metastasis. In addition, by using multivalent peptide library screening based on peptide3A5, we then isolated two more candidates; divalent ILVIK, and tetravalent ILVIK. Of note, multivalent ILVIK, but not monovalent ILVIK showed competitive inhibitory activity against TLR4/MD-2 complex, and anti-tumoral activity in SW480 xenograft models. As most tumor cells including SW480 cells also express TLR4, S100A8 inhibitory peptides would target both the tumor microenvironment and tumor cells. Thus, multivalent S100A8 inhibitory peptides would provide new pharmaceutical options for aggressive cancers.
AbstractList The tumor-elicited inflammation is closely related to tumor microenvironment during tumor progression. S100A8, an endogenous ligand of Toll-like receptor 4 (TLR4), is known as a key molecule in the tumor microenvironment and premetastatic niche formation. We firstly generated a novel multivalent S100A8 competitive inhibitory peptide (divalent peptide3A5) against TLR4/MD-2, using the alanine scanning. Divalent peptide3A5 suppressed S100A8-mediated interleukin-8 and vascular endothelial growth factor production in human colorectal tumor SW480 cells. Using SW480-transplanted xenograft models, divalent peptide3A5 suppressed tumor progression in a dose-dependent manner. We demonstrated that combination therapy with divalent peptide3A5 and bevacizumab synergistically suppressed tumor growth in SW480 xenograft models. Using syngeneic mouse models, we found that divalent peptide3A5 improved the efficacy of anti-programmed death (PD)1 antibody, and lung metastasis. In addition, by using multivalent peptide library screening based on peptide3A5, we then isolated two more candidates; divalent ILVIK, and tetravalent ILVIK. Of note, multivalent ILVIK, but not monovalent ILVIK showed competitive inhibitory activity against TLR4/MD-2 complex, and anti-tumoral activity in SW480 xenograft models. As most tumor cells including SW480 cells also express TLR4, S100A8 inhibitory peptides would target both the tumor microenvironment and tumor cells. Thus, multivalent S100A8 inhibitory peptides would provide new pharmaceutical options for aggressive cancers.
Abstract The tumor-elicited inflammation is closely related to tumor microenvironment during tumor progression. S100A8 , an endogenous ligand of Toll-like receptor 4 (TLR4), is known as a key molecule in the tumor microenvironment and premetastatic niche formation. We firstly generated a novel multivalent S100A8 competitive inhibitory peptide (divalent peptide3A5) against TLR4/MD-2, using the alanine scanning. Divalent peptide3A5 suppressed S100A8-mediated interleukin-8 and vascular endothelial growth factor production in human colorectal tumor SW480 cells. Using SW480-transplanted xenograft models, divalent peptide3A5 suppressed tumor progression in a dose-dependent manner. We demonstrated that combination therapy with divalent peptide3A5 and bevacizumab synergistically suppressed tumor growth in SW480 xenograft models. Using syngeneic mouse models, we found that divalent peptide3A5 improved the efficacy of anti-programmed death (PD)1 antibody, and lung metastasis. In addition, by using multivalent peptide library screening based on peptide3A5, we then isolated two more candidates; divalent ILVIK, and tetravalent ILVIK. Of note, multivalent ILVIK, but not monovalent ILVIK showed competitive inhibitory activity against TLR4/MD-2 complex, and anti-tumoral activity in SW480 xenograft models. As most tumor cells including SW480 cells also express TLR4, S100A8 inhibitory peptides would target both the tumor microenvironment and tumor cells. Thus, multivalent S100A8 inhibitory peptides would provide new pharmaceutical options for aggressive cancers.
The tumor-elicited inflammation is closely related to tumor microenvironment during tumor progression. S100A8 , an endogenous ligand of Toll-like receptor 4 (TLR4), is known as a key molecule in the tumor microenvironment and premetastatic niche formation. We firstly generated a novel multivalent S100A8 competitive inhibitory peptide (divalent peptide3A5) against TLR4/MD-2, using the alanine scanning. Divalent peptide3A5 suppressed S100A8-mediated interleukin-8 and vascular endothelial growth factor production in human colorectal tumor SW480 cells. Using SW480-transplanted xenograft models, divalent peptide3A5 suppressed tumor progression in a dose-dependent manner. We demonstrated that combination therapy with divalent peptide3A5 and bevacizumab synergistically suppressed tumor growth in SW480 xenograft models. Using syngeneic mouse models, we found that divalent peptide3A5 improved the efficacy of anti-programmed death (PD)1 antibody, and lung metastasis. In addition, by using multivalent peptide library screening based on peptide3A5, we then isolated two more candidates; divalent ILVIK, and tetravalent ILVIK. Of note, multivalent ILVIK, but not monovalent ILVIK showed competitive inhibitory activity against TLR4/MD-2 complex, and anti-tumoral activity in SW480 xenograft models. As most tumor cells including SW480 cells also express TLR4, S100A8 inhibitory peptides would target both the tumor microenvironment and tumor cells. Thus, multivalent S100A8 inhibitory peptides would provide new pharmaceutical options for aggressive cancers.
Author Mishima, Taishi
Nakamura, Fumio
Maru, Yoshiro
Nishikawa, Kiyotaka
Deguchi, Atsuko
Watanabe-Takahashi, Miho
Arashiki, Nobuto
Omori, Tsutomu
Ohto, Umeharu
Author_xml – sequence: 1
  givenname: Atsuko
  orcidid: 0000-0001-9647-3539
  surname: Deguchi
  fullname: Deguchi, Atsuko
  email: adeguchi@twmu.ac.jp
  organization: Department of Pharmacology, Tokyo Women’s Medical University
– sequence: 2
  givenname: Miho
  surname: Watanabe-Takahashi
  fullname: Watanabe-Takahashi, Miho
  organization: Faculty of Life and Medical Sciences, Doshisha University
– sequence: 3
  givenname: Taishi
  surname: Mishima
  fullname: Mishima, Taishi
  organization: Department of Pharmacology, Tokyo Women’s Medical University
– sequence: 4
  givenname: Tsutomu
  surname: Omori
  fullname: Omori, Tsutomu
  organization: Department of Pharmacology, Tokyo Women’s Medical University
– sequence: 5
  givenname: Umeharu
  orcidid: 0000-0002-4422-4044
  surname: Ohto
  fullname: Ohto, Umeharu
  organization: Graduate School of Pharmaceutical Sciences, The University of Tokyo
– sequence: 6
  givenname: Nobuto
  orcidid: 0000-0001-5306-9405
  surname: Arashiki
  fullname: Arashiki, Nobuto
  organization: Department of Biochemistry, Tokyo Women’s Medical University
– sequence: 7
  givenname: Fumio
  surname: Nakamura
  fullname: Nakamura, Fumio
  organization: Department of Biochemistry, Tokyo Women’s Medical University
– sequence: 8
  givenname: Kiyotaka
  surname: Nishikawa
  fullname: Nishikawa, Kiyotaka
  email: knishika@mail.doshisha.ac.jp
  organization: Faculty of Life and Medical Sciences, Doshisha University
– sequence: 9
  givenname: Yoshiro
  orcidid: 0000-0002-9477-7974
  surname: Maru
  fullname: Maru, Yoshiro
  email: maru.yoshiro@twmu.ac.jp
  organization: Department of Pharmacology, Tokyo Women’s Medical University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36932197$$D View this record in MEDLINE/PubMed
BookMark eNp9kU2LFDEQhoOsuLOrf8CDBLx4ieaj00kfl8UvGBR0PYeku3omS3fSJumVufnTzTi7Ch6EQA711FtFPRfoLMQACD1n9DWjQr_JDWuYIpQLQmlLGyIeoQ1rVEukpPQMbWjHO8I6Ks7RRc63lNaiEk_QuWg7wVmnNujnp3gHE57Xqfg7O0Eo-Cuj9EpjH_be-RLTAS-wFD9AxrYUCKstgMs6x4SXFHcJcvYxYBsGPEOxuT6fsTs8JPiww2UP-Gb7pSEDLBCG45jFlv0Pe3iKHo92yvDs_r9E3969vbn-QLaf33-8vtqSvtGyENvJvuvl0DjF7WA7AaMbWcuk7dnY67YZtObSgdKKc6msUMrZno5OjdQJzcUlenXKrTt_XyEXM_vcwzTZAHHNhiutVafqxSr68h_0Nq4p1O0M1-KISd1Wip-oPsWcE4xmSX626WAYNUc_5uTHVD_mtx8jatOL--jVzTD8aXkQUgFxAnIthR2kv7P_E_sLcsOe0A
CitedBy_id crossref_primary_10_1016_j_celrep_2023_113006
crossref_primary_10_3390_molecules29122727
Cites_doi 10.1073/pnas.1003893107
10.1172/JCI23755
10.1038/nature04186
10.1128/AEM.03517-14
10.1084/jem.20080132
10.1038/nm1315
10.1038/nm.3560
10.1096/fj.06-6572fje
10.1126/science.1090922
10.1016/S0140-6736(00)49915-0
10.1073/pnas.1201193109
10.3389/fonc.2018.00496
10.1126/scisignal.2001868
10.1158/0008-5472.CAN-10-2833
10.1038/nm.2851
10.4049/jimmunol.1900753
10.1038/ncb1507
10.1016/j.cell.2020.08.002
10.4049/jimmunol.168.10.5233
10.1038/leu.2010.251
10.1158/0008-5472.CAN-19-0053
10.1038/onc.2015.211
10.1038/nature07830
10.1186/s40425-019-0828-1
10.4049/jimmunol.1201996
10.1016/j.cell.2007.08.002
10.1074/jbc.M100099200
10.1189/jlb.70.1.59
10.1126/science.1075565
10.1016/j.ajpath.2012.09.007
10.1038/nm1638
10.1038/nm1663
10.1038/ni.1863
10.4049/jimmunol.167.5.2887
10.1074/jbc.M200497200
10.1038/ncb1794
10.1074/jbc.M103217200
10.4049/jimmunol.173.9.5398
10.1038/onc.2011.53
10.1038/s41577-020-00490-y
10.1124/mol.105.019695
ContentType Journal Article
Copyright The Author(s) 2023
2023. The Author(s).
The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2023
– notice: 2023. The Author(s).
– notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
NPM
AAYXX
CITATION
3V.
7QP
7TK
7TM
7TO
7U9
7X7
7XB
88A
88E
8AO
8C1
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
P64
PQEST
PQQKQ
PQUKI
RC3
7X8
DOI 10.1038/s41417-023-00604-3
DatabaseName SpringerOpen
PubMed
CrossRef
ProQuest Central (Corporate)
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni Edition)
Medical Database
Biological Science Database
Biotechnology and BioEngineering Abstracts
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
Technology Research Database
ProQuest Central Essentials
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
Genetics Abstracts
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Medical Library (Alumni)
ProQuest Public Health
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest Central Student
CrossRef

PubMed
Database_xml – sequence: 1
  dbid: C6C
  name: SpringerOpen
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1476-5500
EndPage 984
ExternalDocumentID 10_1038_s41417_023_00604_3
36932197
Genre Journal Article
GrantInformation_xml – fundername: Japan Agency for Medical Research and Development (AMED)
  grantid: JP21cm0106281
  funderid: https://doi.org/10.13039/100009619
– fundername: Astellas Foundation for Research on Metabolic Disorders
  funderid: https://doi.org/10.13039/501100007263
– fundername: Takeda Science Foundation
  funderid: https://doi.org/10.13039/100007449
– fundername: MEXT | Japan Society for the Promotion of Science (JSPS)
  grantid: JP18K07245; JP21K07157; JP19H03506
  funderid: https://doi.org/10.13039/501100001691
– fundername: MEXT | Japan Society for the Promotion of Science (JSPS)
  grantid: JP19H03506
– fundername: MEXT | Japan Society for the Promotion of Science (JSPS)
  grantid: JP21K07157
– fundername: Japan Agency for Medical Research and Development (AMED)
  grantid: JP21cm0106281
– fundername: MEXT | Japan Society for the Promotion of Science (JSPS)
  grantid: JP18K07245
GroupedDBID ---
0R~
29B
2WC
36B
39C
3V.
4.4
406
53G
5GY
5RE
6J9
70F
7X7
88A
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8R4
8R5
AACDK
AANZL
AASML
AATNV
AAWBL
AAZLF
ABAKF
ABAWZ
ABDBF
ABHFT
ABJNI
ABLJU
ABUWG
ABZZP
ACAOD
ACGFO
ACGFS
ACKTT
ACMJI
ACPRK
ACRQY
ACZOJ
ADBBV
ADFRT
ADHDB
AEFQL
AEJRE
AEMSY
AENEX
AEVLU
AEXYK
AFBBN
AFKRA
AFSHS
AGAYW
AGEZK
AGHAI
AGQEE
AHMBA
AHSBF
AIGIU
AILAN
AJRNO
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMYLF
ASPBG
AVWKF
AXYYD
AZFZN
B0M
BAWUL
BBNVY
BENPR
BHPHI
BKKNO
BPHCQ
BVXVI
C6C
CAG
CCPQU
COF
CS3
DIK
DNIVK
DPUIP
DU5
E3Z
EAD
EAP
EBC
EBD
EBLON
EBS
EE.
EIOEI
EJD
EMB
EMK
EMOBN
EPL
ESX
F5P
FD6
FDQFY
FERAY
FIGPU
FIZPM
FRP
FSGXE
FYUFA
HCIFZ
HMCUK
HZ~
IAO
IH2
IHR
IHW
INH
INR
ITC
IWAJR
JSO
JZLTJ
KQ8
LGEZI
LK8
LMP
LOTEE
M0L
M1P
M7P
NADUK
NAO
NQJWS
NXXTH
O9-
OK1
OVD
P2P
PQQKQ
PROAC
PSQYO
Q2X
RIG
RNS
RNT
RNTTT
SNX
SNYQT
SOHCF
SRMVM
SV3
SWTZT
TAOOD
TBHMF
TDRGL
TEORI
TR2
TSG
TUS
UDS
UKHRP
~8M
AAYZH
NPM
AAYXX
CITATION
7QP
7TK
7TM
7TO
7U9
7XB
8FD
8FK
AZQEC
DWQXO
FR3
GNUQQ
H94
K9.
P64
PQEST
PQUKI
RC3
7X8
ID FETCH-LOGICAL-c485t-a95c9c5d4b72ada93efbf1615ac1fc864d8825be7872257a377bac0fb7f0b3823
IEDL.DBID C6C
ISSN 0929-1903
IngestDate Fri Oct 25 21:28:51 EDT 2024
Thu Oct 10 22:03:30 EDT 2024
Thu Sep 26 19:23:46 EDT 2024
Wed Oct 16 00:38:39 EDT 2024
Fri Oct 11 20:50:47 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
License 2023. The Author(s).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c485t-a95c9c5d4b72ada93efbf1615ac1fc864d8825be7872257a377bac0fb7f0b3823
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-9477-7974
0000-0001-9647-3539
0000-0001-5306-9405
0000-0002-4422-4044
OpenAccessLink https://doi.org/10.1038/s41417-023-00604-3
PMID 36932197
PQID 2838879586
PQPubID 32245
PageCount 12
ParticipantIDs proquest_miscellaneous_2788797929
proquest_journals_2838879586
crossref_primary_10_1038_s41417_023_00604_3
pubmed_primary_36932197
springer_journals_10_1038_s41417_023_00604_3
PublicationCentury 2000
PublicationDate 2023-07-01
PublicationDateYYYYMMDD 2023-07-01
PublicationDate_xml – month: 07
  year: 2023
  text: 2023-07-01
  day: 01
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
– name: England
– name: San Diego
PublicationTitle Cancer gene therapy
PublicationTitleAbbrev Cancer Gene Ther
PublicationTitleAlternate Cancer Gene Ther
PublicationYear 2023
Publisher Nature Publishing Group US
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group US
– name: Nature Publishing Group
References Hsu, Chan, Spicer, Rousseau, Giannias, Rousseau (CR27) 2011; 71
Seki, De Minicis, Osterreicher, Kluwe, Osawa, Brenner (CR39) 2007; 13
Nishikawa, Watanabe, Kita, Igai, Omata, Yaffe (CR23) 2006; 20
Cheng, Corzo, Luetteke, Yu, Nagaraj, Bui (CR26) 2008; 205
Biragyn, Ruffini, Leifer, Klyushnenkova, Shakhov, Chertov (CR13) 2002; 298
Li, Wang, Zhang, Liu, Zhang, Wang (CR29) 2020; 204
Jiang, Liang, Fan, Yu, Chen, Luo (CR16) 2005; 11
Merline, Moreth, Beckmann, Nastase, Zeng-Brouwers, Tralhao (CR19) 2011; 4
Kaplan, Riba, Zacharoulis, Bramley, Vincent, Costa (CR3) 2005; 438
Pal, Dasgupta, Kundu, Maitra, Das, Mukhopadhyay (CR12) 2012; 18
Kato, Watanabe-Takahashi, Shimizu, Nishikawa (CR24) 2015; 81
Fleming, Hu, Weller, Weber, Groth, Riester (CR38) 2019; 79
CR34
Smiley, King, Hancock (CR14) 2001; 167
Yang, Hreggvidsdottir, Palmblad, Wang, Ochani, Li (CR7) 2010; 107
Tomita, Sakurai, Ishibashi, Maru (CR28) 2011; 30
Kim, Park, Kim, Kim, Lee, Oh (CR33) 2007; 130
Silvin, Chapuis, Dunsmore, Goubet, Dubuisson, Derosa (CR42) 2020; 182
Asea, Rehli, Kabingu, Boch, Bare, Auron (CR11) 2002; 277
Kumar, Yang, Bilson, Thliveris, Cooke, Geczy (CR21) 2001; 70
Johnson, Brunn, Kodaira, Platt (CR17) 2002; 168
Wang, Liu, Wu, Chen, Zeng, Pan (CR36) 2018; 8
Vabulas, Ahmad-Nejad, da Costa, Miethke, Kirschning, Hacker (CR10) 2001; 276
Schaefer, Babelova, Kiss, Hausser, Baliova, Krzyzankova (CR18) 2005; 115
Hiratsuka, Watanabe, Aburatani, Maru (CR4) 2006; 8
Bhowmick, Chytil, Plieth, Gorska, Dumont, Shappell (CR40) 2004; 303
Deguchi, Tomita, Omori, Komatsu, Ohto, Takahashi (CR9) 2013; 191
Pan, Hu, Hu, Xu, Chen, Du (CR30) 2020; 56
Hiratsuka, Watanabe, Sakurai, Akashi-Takamura, Ishibashi, Miyake (CR1) 2008; 10
Deguchi, Tomita, Ohto, Takemura, Kitao, Akashi-Takamura (CR8) 2016; 35
Vora, Youdim, Thomas, Fukata, Tesfay, Lukasek (CR32) 2004; 173
Paget (CR2) 1889; 133
Nicolas, Ramus, Berthier, Arlotto, Bouamrani, Lefebvre (CR37) 2011; 25
Qin, Lerman, Sakamaki, Wei, Cha, Rao (CR35) 2014; 20
Wagner, Weide, Gries, Reith, Tarnanidis, Schuermans (CR31) 2019; 7
Veglia, Sanseviero, Gabrilovich (CR22) 2021; 21
Ohto, Fukase, Miyake, Shimizu (CR25) 2012; 109
Okamura, Watari, Jerud, Young, Ishizaka, Rose (CR15) 2001; 276
Park, Song, Kim, Choi, Lee, Lee (CR20) 2009; 458
Kawai, Akira (CR6) 2010; 11
Bhattacharyya, Kelley, Melichian, Tamaki, Fang, Su (CR41) 2013; 182
Vogl, Tenbrock, Ludwig, Leukert, Ehrhardt, van Zoelen (CR5) 2007; 13
NB Wagner (604_CR31) 2019; 7
V Fleming (604_CR38) 2019; 79
L Schaefer (604_CR18) 2005; 115
E Nicolas (604_CR37) 2011; 25
RN Kaplan (604_CR3) 2005; 438
GB Johnson (604_CR17) 2002; 168
T Tomita (604_CR28) 2011; 30
HM Kim (604_CR33) 2007; 130
RY Hsu (604_CR27) 2011; 71
K Nishikawa (604_CR23) 2006; 20
PY Cheng (604_CR26) 2008; 205
A Biragyn (604_CR13) 2002; 298
R Merline (604_CR19) 2011; 4
Z Li (604_CR29) 2020; 204
A Deguchi (604_CR9) 2013; 191
D Pal (604_CR12) 2012; 18
P Vora (604_CR32) 2004; 173
T Vogl (604_CR5) 2007; 13
RM Vabulas (604_CR10) 2001; 276
M Kato (604_CR24) 2015; 81
A Asea (604_CR11) 2002; 277
A Deguchi (604_CR8) 2016; 35
Y Okamura (604_CR15) 2001; 276
NA Bhowmick (604_CR40) 2004; 303
RK Kumar (604_CR21) 2001; 70
F Veglia (604_CR22) 2021; 21
S Paget (604_CR2) 1889; 133
604_CR34
S Hiratsuka (604_CR4) 2006; 8
BS Park (604_CR20) 2009; 458
T Kawai (604_CR6) 2010; 11
U Ohto (604_CR25) 2012; 109
H Qin (604_CR35) 2014; 20
DJ Wang (604_CR36) 2018; 8
S Hiratsuka (604_CR1) 2008; 10
D Jiang (604_CR16) 2005; 11
A Silvin (604_CR42) 2020; 182
S Pan (604_CR30) 2020; 56
S Bhattacharyya (604_CR41) 2013; 182
ST Smiley (604_CR14) 2001; 167
E Seki (604_CR39) 2007; 13
H Yang (604_CR7) 2010; 107
References_xml – volume: 107
  start-page: 11942
  year: 2010
  end-page: 47
  ident: CR7
  article-title: A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1003893107
  contributor:
    fullname: Li
– volume: 115
  start-page: 2223
  year: 2005
  end-page: 33
  ident: CR18
  article-title: The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages
  publication-title: J Clin Invest
  doi: 10.1172/JCI23755
  contributor:
    fullname: Krzyzankova
– volume: 438
  start-page: 820
  year: 2005
  end-page: 27
  ident: CR3
  article-title: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
  publication-title: Nature.
  doi: 10.1038/nature04186
  contributor:
    fullname: Costa
– volume: 81
  start-page: 1092
  year: 2015
  end-page: 100
  ident: CR24
  article-title: Identification of a wide range of motifs inhibitory to Shiga toxin by affinity-driven screening of customized divalent peptides synthesized on a membrane
  publication-title: Appl Environ Microb
  doi: 10.1128/AEM.03517-14
  contributor:
    fullname: Nishikawa
– volume: 205
  start-page: 2235
  year: 2008
  end-page: 49
  ident: CR26
  article-title: Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein
  publication-title: J Exp Med
  doi: 10.1084/jem.20080132
  contributor:
    fullname: Bui
– volume: 11
  start-page: 1173
  year: 2005
  end-page: 79
  ident: CR16
  article-title: Regulation of lung injury and repair by Toll-like receptors and hyaluronan
  publication-title: Nat Med
  doi: 10.1038/nm1315
  contributor:
    fullname: Luo
– volume: 20
  start-page: 676
  year: 2014
  end-page: 81
  ident: CR35
  article-title: Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice
  publication-title: Nat Med
  doi: 10.1038/nm.3560
  contributor:
    fullname: Rao
– volume: 20
  start-page: 2597
  year: 2006
  end-page: 99
  ident: CR23
  article-title: A multivalent peptide library approach identifies a novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin
  publication-title: FASEB J
  doi: 10.1096/fj.06-6572fje
  contributor:
    fullname: Yaffe
– volume: 303
  start-page: 848
  year: 2004
  end-page: 51
  ident: CR40
  article-title: TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia
  publication-title: Science.
  doi: 10.1126/science.1090922
  contributor:
    fullname: Shappell
– volume: 133
  start-page: 571
  year: 1889
  end-page: 73
  ident: CR2
  article-title: The distribution of secondary growths in cancer of the breast
  publication-title: Lancet
  doi: 10.1016/S0140-6736(00)49915-0
  contributor:
    fullname: Paget
– volume: 109
  start-page: 7421
  year: 2012
  end-page: 26
  ident: CR25
  article-title: Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1201193109
  contributor:
    fullname: Shimizu
– volume: 8
  start-page: 496
  year: 2018
  ident: CR36
  article-title: Clinical significance of elevated S100A8 expression in breast cancer patients
  publication-title: Front Oncol
  doi: 10.3389/fonc.2018.00496
  contributor:
    fullname: Pan
– volume: 4
  start-page: ra75
  year: 2011
  ident: CR19
  article-title: Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21
  publication-title: Sci Signal
  doi: 10.1126/scisignal.2001868
  contributor:
    fullname: Tralhao
– volume: 71
  start-page: 1989
  year: 2011
  end-page: 98
  ident: CR27
  article-title: LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-2833
  contributor:
    fullname: Rousseau
– volume: 18
  start-page: 1279
  year: 2012
  end-page: 85
  ident: CR12
  article-title: Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance
  publication-title: Nat Med
  doi: 10.1038/nm.2851
  contributor:
    fullname: Mukhopadhyay
– volume: 204
  start-page: 2589
  year: 2020
  end-page: 99
  ident: CR29
  article-title: Proinflammatory S100A8 induces PD-L1 expression in macrophages, mediating tumor immune escape
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1900753
  contributor:
    fullname: Wang
– volume: 8
  start-page: 1369
  year: 2006
  end-page: 75
  ident: CR4
  article-title: Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb1507
  contributor:
    fullname: Maru
– volume: 182
  start-page: 1401
  year: 2020
  end-page: 18
  ident: CR42
  article-title: Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19
  publication-title: Cell.
  doi: 10.1016/j.cell.2020.08.002
  contributor:
    fullname: Derosa
– volume: 168
  start-page: 5233
  year: 2002
  end-page: 39
  ident: CR17
  article-title: Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4
  publication-title: J Immunol
  doi: 10.4049/jimmunol.168.10.5233
  contributor:
    fullname: Platt
– volume: 25
  start-page: 57
  year: 2011
  end-page: 65
  ident: CR37
  article-title: Expression of S100A8 in leukemic cells predicts poor survival in de novo AML patients
  publication-title: Leukemia.
  doi: 10.1038/leu.2010.251
  contributor:
    fullname: Lefebvre
– volume: 79
  start-page: 4715
  year: 2019
  end-page: 28
  ident: CR38
  article-title: Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 Signaling
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-19-0053
  contributor:
    fullname: Riester
– volume: 35
  start-page: 1445
  year: 2016
  end-page: 56
  ident: CR8
  article-title: Eritoran inhibits S100A8-mediated TLR4/MD-2 activation and tumor growth by changing the immune microenvironment
  publication-title: Oncogene.
  doi: 10.1038/onc.2015.211
  contributor:
    fullname: Akashi-Takamura
– volume: 458
  start-page: 1191
  year: 2009
  end-page: 95
  ident: CR20
  article-title: The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex
  publication-title: Nature.
  doi: 10.1038/nature07830
  contributor:
    fullname: Lee
– volume: 7
  start-page: 343
  year: 2019
  ident: CR31
  article-title: Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-019-0828-1
  contributor:
    fullname: Schuermans
– volume: 191
  start-page: 1856
  year: 2013
  end-page: 64
  ident: CR9
  article-title: Serum amyloid A3 binds MD-2 to activate p38 and NF-kappaB pathways in a MyD88-dependent manner
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1201996
  contributor:
    fullname: Takahashi
– volume: 130
  start-page: 906
  year: 2007
  end-page: 17
  ident: CR33
  article-title: Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran
  publication-title: Cell.
  doi: 10.1016/j.cell.2007.08.002
  contributor:
    fullname: Oh
– volume: 276
  start-page: 10229
  year: 2001
  end-page: 33
  ident: CR15
  article-title: The extra domain A of fibronectin activates Toll-like receptor 4
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M100099200
  contributor:
    fullname: Rose
– volume: 70
  start-page: 59
  year: 2001
  end-page: 64
  ident: CR21
  article-title: Dimeric S100A8 in human neutrophils is diminished after phagocytosis
  publication-title: J Leukoc Biol
  doi: 10.1189/jlb.70.1.59
  contributor:
    fullname: Geczy
– volume: 298
  start-page: 1025
  year: 2002
  end-page: 29
  ident: CR13
  article-title: Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2
  publication-title: Science.
  doi: 10.1126/science.1075565
  contributor:
    fullname: Chertov
– volume: 182
  start-page: 192
  year: 2013
  end-page: 205
  ident: CR41
  article-title: Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma
  publication-title: Am J Pathol
  doi: 10.1016/j.ajpath.2012.09.007
  contributor:
    fullname: Su
– volume: 13
  start-page: 1042
  year: 2007
  end-page: 49
  ident: CR5
  article-title: Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock
  publication-title: Nat Med
  doi: 10.1038/nm1638
  contributor:
    fullname: van Zoelen
– ident: CR34
– volume: 13
  start-page: 1324
  year: 2007
  end-page: 32
  ident: CR39
  article-title: TLR4 enhances TGF-β signaling and hepatic fibrosis
  publication-title: Nat Med
  doi: 10.1038/nm1663
  contributor:
    fullname: Brenner
– volume: 11
  start-page: 373
  year: 2010
  end-page: 84
  ident: CR6
  article-title: The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
  publication-title: Nat Immunol
  doi: 10.1038/ni.1863
  contributor:
    fullname: Akira
– volume: 167
  start-page: 2887
  year: 2001
  end-page: 94
  ident: CR14
  article-title: Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4
  publication-title: J Immunol
  doi: 10.4049/jimmunol.167.5.2887
  contributor:
    fullname: Hancock
– volume: 277
  start-page: 15028
  year: 2002
  end-page: 34
  ident: CR11
  article-title: Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M200497200
  contributor:
    fullname: Auron
– volume: 56
  start-page: 101
  year: 2020
  end-page: 12
  ident: CR30
  article-title: S100A8 facilitates cholangiocarcinoma metastasis via upregulation of VEGF through TLR4/NF-κB pathway activation
  publication-title: Int J Oncol
  contributor:
    fullname: Du
– volume: 10
  start-page: 1349
  year: 2008
  end-page: 55
  ident: CR1
  article-title: The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb1794
  contributor:
    fullname: Miyake
– volume: 276
  start-page: 31332
  year: 2001
  end-page: 39
  ident: CR10
  article-title: Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M103217200
  contributor:
    fullname: Hacker
– volume: 173
  start-page: 5398
  year: 2004
  end-page: 405
  ident: CR32
  article-title: beta-Defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells
  publication-title: J Immunol
  doi: 10.4049/jimmunol.173.9.5398
  contributor:
    fullname: Lukasek
– volume: 30
  start-page: 3429
  year: 2011
  end-page: 39
  ident: CR28
  article-title: Imbalance of Clara cell-mediated homeostatic inflammation is involved in lung metastasis
  publication-title: Oncogene.
  doi: 10.1038/onc.2011.53
  contributor:
    fullname: Maru
– volume: 21
  start-page: 485
  year: 2021
  end-page: 98
  ident: CR22
  article-title: Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-020-00490-y
  contributor:
    fullname: Gabrilovich
– volume: 8
  start-page: 1369
  year: 2006
  ident: 604_CR4
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb1507
  contributor:
    fullname: S Hiratsuka
– volume: 276
  start-page: 31332
  year: 2001
  ident: 604_CR10
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M103217200
  contributor:
    fullname: RM Vabulas
– volume: 13
  start-page: 1042
  year: 2007
  ident: 604_CR5
  publication-title: Nat Med
  doi: 10.1038/nm1638
  contributor:
    fullname: T Vogl
– volume: 277
  start-page: 15028
  year: 2002
  ident: 604_CR11
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M200497200
  contributor:
    fullname: A Asea
– volume: 109
  start-page: 7421
  year: 2012
  ident: 604_CR25
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1201193109
  contributor:
    fullname: U Ohto
– volume: 204
  start-page: 2589
  year: 2020
  ident: 604_CR29
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1900753
  contributor:
    fullname: Z Li
– volume: 298
  start-page: 1025
  year: 2002
  ident: 604_CR13
  publication-title: Science.
  doi: 10.1126/science.1075565
  contributor:
    fullname: A Biragyn
– volume: 168
  start-page: 5233
  year: 2002
  ident: 604_CR17
  publication-title: J Immunol
  doi: 10.4049/jimmunol.168.10.5233
  contributor:
    fullname: GB Johnson
– volume: 130
  start-page: 906
  year: 2007
  ident: 604_CR33
  publication-title: Cell.
  doi: 10.1016/j.cell.2007.08.002
  contributor:
    fullname: HM Kim
– volume: 10
  start-page: 1349
  year: 2008
  ident: 604_CR1
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb1794
  contributor:
    fullname: S Hiratsuka
– volume: 11
  start-page: 373
  year: 2010
  ident: 604_CR6
  publication-title: Nat Immunol
  doi: 10.1038/ni.1863
  contributor:
    fullname: T Kawai
– volume: 191
  start-page: 1856
  year: 2013
  ident: 604_CR9
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1201996
  contributor:
    fullname: A Deguchi
– volume: 276
  start-page: 10229
  year: 2001
  ident: 604_CR15
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M100099200
  contributor:
    fullname: Y Okamura
– volume: 21
  start-page: 485
  year: 2021
  ident: 604_CR22
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-020-00490-y
  contributor:
    fullname: F Veglia
– volume: 20
  start-page: 676
  year: 2014
  ident: 604_CR35
  publication-title: Nat Med
  doi: 10.1038/nm.3560
  contributor:
    fullname: H Qin
– volume: 182
  start-page: 192
  year: 2013
  ident: 604_CR41
  publication-title: Am J Pathol
  doi: 10.1016/j.ajpath.2012.09.007
  contributor:
    fullname: S Bhattacharyya
– volume: 205
  start-page: 2235
  year: 2008
  ident: 604_CR26
  publication-title: J Exp Med
  doi: 10.1084/jem.20080132
  contributor:
    fullname: PY Cheng
– volume: 30
  start-page: 3429
  year: 2011
  ident: 604_CR28
  publication-title: Oncogene.
  doi: 10.1038/onc.2011.53
  contributor:
    fullname: T Tomita
– volume: 107
  start-page: 11942
  year: 2010
  ident: 604_CR7
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1003893107
  contributor:
    fullname: H Yang
– volume: 458
  start-page: 1191
  year: 2009
  ident: 604_CR20
  publication-title: Nature.
  doi: 10.1038/nature07830
  contributor:
    fullname: BS Park
– volume: 7
  start-page: 343
  year: 2019
  ident: 604_CR31
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-019-0828-1
  contributor:
    fullname: NB Wagner
– volume: 35
  start-page: 1445
  year: 2016
  ident: 604_CR8
  publication-title: Oncogene.
  doi: 10.1038/onc.2015.211
  contributor:
    fullname: A Deguchi
– volume: 4
  start-page: ra75
  year: 2011
  ident: 604_CR19
  publication-title: Sci Signal
  doi: 10.1126/scisignal.2001868
  contributor:
    fullname: R Merline
– volume: 20
  start-page: 2597
  year: 2006
  ident: 604_CR23
  publication-title: FASEB J
  doi: 10.1096/fj.06-6572fje
  contributor:
    fullname: K Nishikawa
– volume: 8
  start-page: 496
  year: 2018
  ident: 604_CR36
  publication-title: Front Oncol
  doi: 10.3389/fonc.2018.00496
  contributor:
    fullname: DJ Wang
– ident: 604_CR34
  doi: 10.1124/mol.105.019695
– volume: 25
  start-page: 57
  year: 2011
  ident: 604_CR37
  publication-title: Leukemia.
  doi: 10.1038/leu.2010.251
  contributor:
    fullname: E Nicolas
– volume: 18
  start-page: 1279
  year: 2012
  ident: 604_CR12
  publication-title: Nat Med
  doi: 10.1038/nm.2851
  contributor:
    fullname: D Pal
– volume: 303
  start-page: 848
  year: 2004
  ident: 604_CR40
  publication-title: Science.
  doi: 10.1126/science.1090922
  contributor:
    fullname: NA Bhowmick
– volume: 70
  start-page: 59
  year: 2001
  ident: 604_CR21
  publication-title: J Leukoc Biol
  doi: 10.1189/jlb.70.1.59
  contributor:
    fullname: RK Kumar
– volume: 182
  start-page: 1401
  year: 2020
  ident: 604_CR42
  publication-title: Cell.
  doi: 10.1016/j.cell.2020.08.002
  contributor:
    fullname: A Silvin
– volume: 81
  start-page: 1092
  year: 2015
  ident: 604_CR24
  publication-title: Appl Environ Microb
  doi: 10.1128/AEM.03517-14
  contributor:
    fullname: M Kato
– volume: 79
  start-page: 4715
  year: 2019
  ident: 604_CR38
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-19-0053
  contributor:
    fullname: V Fleming
– volume: 133
  start-page: 571
  year: 1889
  ident: 604_CR2
  publication-title: Lancet
  doi: 10.1016/S0140-6736(00)49915-0
  contributor:
    fullname: S Paget
– volume: 167
  start-page: 2887
  year: 2001
  ident: 604_CR14
  publication-title: J Immunol
  doi: 10.4049/jimmunol.167.5.2887
  contributor:
    fullname: ST Smiley
– volume: 71
  start-page: 1989
  year: 2011
  ident: 604_CR27
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-2833
  contributor:
    fullname: RY Hsu
– volume: 11
  start-page: 1173
  year: 2005
  ident: 604_CR16
  publication-title: Nat Med
  doi: 10.1038/nm1315
  contributor:
    fullname: D Jiang
– volume: 115
  start-page: 2223
  year: 2005
  ident: 604_CR18
  publication-title: J Clin Invest
  doi: 10.1172/JCI23755
  contributor:
    fullname: L Schaefer
– volume: 173
  start-page: 5398
  year: 2004
  ident: 604_CR32
  publication-title: J Immunol
  doi: 10.4049/jimmunol.173.9.5398
  contributor:
    fullname: P Vora
– volume: 13
  start-page: 1324
  year: 2007
  ident: 604_CR39
  publication-title: Nat Med
  doi: 10.1038/nm1663
  contributor:
    fullname: E Seki
– volume: 438
  start-page: 820
  year: 2005
  ident: 604_CR3
  publication-title: Nature.
  doi: 10.1038/nature04186
  contributor:
    fullname: RN Kaplan
– volume: 56
  start-page: 101
  year: 2020
  ident: 604_CR30
  publication-title: Int J Oncol
  contributor:
    fullname: S Pan
SSID ssj0014773
Score 2.442008
Snippet The tumor-elicited inflammation is closely related to tumor microenvironment during tumor progression. S100A8 , an endogenous ligand of Toll-like receptor 4...
The tumor-elicited inflammation is closely related to tumor microenvironment during tumor progression. S100A8, an endogenous ligand of Toll-like receptor 4...
Abstract The tumor-elicited inflammation is closely related to tumor microenvironment during tumor progression. S100A8 , an endogenous ligand of Toll-like...
SourceID proquest
crossref
pubmed
springer
SourceType Aggregation Database
Index Database
Publisher
StartPage 973
SubjectTerms 13/31
13/51
13/95
59
631/67/1059/153
631/67/327
64
64/60
82/75
Alanine
Animal models
Apoptosis
Bevacizumab
Biomedical and Life Sciences
Biomedicine
Cell culture
Gene Expression
Gene Therapy
Interleukin 8
Metastases
Metastasis
Mutagenesis
Peptides
TLR4 protein
Toll-like receptors
Tumor cells
Tumor microenvironment
Tumors
Vascular endothelial growth factor
Xenografts
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fa9UwFD7ohrIX0albdUoE3zSsbZImfZIpG0PcReYGeyv5Vbzg2ru1d-O--ad70qZ3yNDntmnId07OR76TcwDeY4STpeCWalVqyoWQtLSC0cJbmZXeMi3C3eGTWXF8zr9eiIt44NbFtMppTxw2atfacEa-j2FQhcbYqvi0uKKha1RQV2MLjYewmWc8yLSbnw9n30_XOgKXo8aMJIBi6GPx2kzK1H7H8QtJMWbRUJSEU_Z3aLrHN-9ppUMIOnoKTyJ3JAcj2M_ggW-24dHYTXK1DY9Pok7-HH7P2hv_iwzZgmhKGFjIjyxNDxSZNz_nZh6UdbIICS3OdySU2GyWSDpJv7xsr8mQszXW6yC6ceTS9xpJZDfviFlNI-AMCZJHcvbtlNOplW5PQofjW716AedHh2dfjmnstUAtV6KnuhQWQXLcyFw7XTJfmzqwQW2z2qqCO6Tiwnj0b9wBpGZSGm3T2sg6NUFLfAkbTdv4XSA6l0Vai9w5mXPlhMFlNnWufJpqrSxP4MO0zNViLKlRDVI4U9UISoWgVAMoFUtgb0Kiiu7VVXfGkMC79WN0jKB26Ma3S3wn5EmWEpFPYGdEcP07ViBtzUqZwMcJ0rvB_z2XV_-fy2vYygdzCsm8e7DRXy_9G6QsvXkb7fIPLFfobw
  priority: 102
  providerName: ProQuest
Title Novel multivalent S100A8 inhibitory peptides attenuate tumor progression and metastasis by inhibiting the TLR4-dependent pathway
URI https://link.springer.com/article/10.1038/s41417-023-00604-3
https://www.ncbi.nlm.nih.gov/pubmed/36932197
https://www.proquest.com/docview/2838879586
https://search.proquest.com/docview/2788797929
Volume 30
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT9wwEB7xUFEvVaFA08LKSNyoRRLbsXOkKxBCZVXxkPYW2Y4jVmKziGRb7Y2fzjiPrRDlwCWXWI7lbybzSd88AA4xwslUcEu1SjXlQkiaWsFo4qyMUmeZFr52-HKUnN_yi7EYd21yfC3MC_2eqeOKRxz_oxhZqG8dwilbhXURJaG34GEyXCoGXLZqMoZ7ikGOdQUy_9_jZRB6xSxfqaJNsDn7DJ86lkhOWlg3YcWVW_ChnRu52IKNy04R_wJPo9kfd0-avEA0Ggwh5DoKwxNFJuXdxEy8hk4efOpK7irim2mWc6SXpJ5PZ4-kyc5qO3MQXeZk6mqNdLGaVMQs-h3whARpIrn5dcVpPzS3Jn6W8V-92Ibbs9Ob4TntpipQy5WoqU6FRThybmSsc50yV5jC8z5to8KqhOdIuoVx6Mno61IzKY22YWFkERqvGu7AWjkr3VcgOpZJWIg4z2XMVS4MXrMpYuXCUGtleQBH_TVnD23zjKwRvZnKWlAyBCVrQMlYAHs9ElnnSFWG7Ef5eegqCeBg-RpdwOsaunSzOa7xGZGpROQD2G0RXH6OJUhQo1QG8KOH9N_mb5_l2_uWf4ePcWNePo13D9bqx7nbR7JSmwGsyrHEpxpGA1j_eTr6fTVoLPcZ9NLi8g
link.rule.ids 315,786,790,12083,12250,21416,27955,27956,31752,31753,33299,33300,33777,33778,41153,42222,43343,43612,43838,51609,74100,74369,74657
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Nb9QwEB3BVlAuFRRaAgWMxA2sJrEdOyfUVq0W2F2hspV6i2zHESvRZGmyoL3x0xnnY6uqgnMi2_Ibzzz5jWcA3mGEk6nglmqVasqFkDS1gtHEWRmlzjIt_Nvh6SwZX_DPl-Kyv3Cr-7TKwSe2jjqvrL8jP8QwqHxjbJV8XP6kvmuUV1f7Fhr3YcuX3FQj2Do-nX093-gIXHYaM5IAiqGP9c9mQqYOax5x9NAYs6gvSsIpux2a7vDNO1ppG4LOHsNOzx3JUQf2E7jnyl140HWTXO_Cw2mvkz-FP7Pql_tB2mxBNCUMLORbFIZHiizK7wuz8Mo6WfqEltzVxJfYLFdIOkmzuqquSZuz1dXrILrMyZVrNJLIelETsx5GwBUSJI9kPjnndGil2xDf4fi3Xj-Di7PT-cmY9r0WqOVKNFSnwiJIOTcy1rlOmStM4dmgtlFhVcJzpOLCODzf6AGkZlIabcPCyCI0Xkvcg1FZle45EB3LJCxEnOcy5ioXBrfZFLFyYai1sjyA98M2Z8uupEbWSuFMZR0oGYKStaBkLICDAYmsP151dmMMAbzdfMaD4dUOXbpqhf_4PMlUIvIB7HcIbqZjCdLWKJUBfBggvRn832t58f-1vIHt8Xw6ySafZl9ewqO4NS2f2HsAo-Z65V4hfWnM695G_wJRuutl
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Nb9QwEB1BEVUvqJSPBgoYiRtYm8R27JxQVVgVaFcIWmlvlu04YqU22TZZ0N746YzzsRWq4JwoGfmNZ17yxjMAbzDDyVxwR43KDeVCSJo7wWjmnUxy75gR4ezw6Sw7Puef52I-1D81Q1nlGBO7QF3ULvwjn2AaVGEwtsom5VAW8fXD9P3yioYJUkFpHcZp3IV7mCXjMMZBzjcfXwmXvdqMdIBiEmTDAZqYqUnDE46xGrMXDe1JOGV_J6lbzPOWatolo-kuPBhYJDnsYX8Id3y1B_f7uZLrPdg-HRTzR_B7Vv_0F6SrG0SnwhRDvqPZh4osqh8LuwgaO1mG0pbCNyQ026xWSD9Ju7qsr0lXvdV37iCmKsilbw3SyWbRELsen4AWEqSR5OzkG6fjUN2WhFnHv8z6MZxPP54dHdNh6gJ1XImWmlw4hKvgVqamMDnzpS0DLzQuKZ3KeIGkXFiPOx1jgTRMSmtcXFpZxjaoik9gq6orvw_EpDKLS5EWhUy5KoTFZbZlqnwcG6Mcj-DtuMx62TfX0J0ozpTuQdEIiu5A0SyCgxEJPWy0Rt-4RQSvN5dxiwTdw1S-XuE9oWIyl4h8BE97BDevYxkS2CSXEbwbIb15-L9tefZ_W17BNjqnPvk0-_IcdtLOs0KF7wFstdcr_wJ5TGtfdg76BzjE7iI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Novel+multivalent+S100A8+inhibitory+peptides+attenuate+tumor+progression+and+metastasis+by+inhibiting+the+TLR4-dependent+pathway&rft.jtitle=Cancer+gene+therapy&rft.au=Deguchi%2C+Atsuko&rft.au=Watanabe-Takahashi%2C+Miho&rft.au=Mishima%2C+Taishi&rft.au=Omori%2C+Tsutomu&rft.date=2023-07-01&rft.pub=Nature+Publishing+Group+US&rft.issn=0929-1903&rft.eissn=1476-5500&rft.volume=30&rft.issue=7&rft.spage=973&rft.epage=984&rft_id=info:doi/10.1038%2Fs41417-023-00604-3&rft.externalDocID=10_1038_s41417_023_00604_3
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0929-1903&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0929-1903&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0929-1903&client=summon